Compare Aptiv PLC (APTV) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Novavax Inc — how do they compare? Aptiv PLC trades at $50.28 (market cap $10.30B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Aptiv PLC is far larger — about 7.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.
| APTV | NVAX | |
|---|---|---|
Market Cap | $10.30B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $11.19 |
52-Week Low | $46.30 | $6.22 |
Enterprise Value | $15.23B | $889.30M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
